Shares of Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) fell nearly 16.5 percent to close at $98.20 on Thursday as the company reported third-quarter revenue of $5.2 million, primarily attributed to its biliary cholangitis (PBC) therapy, Ocaliva (obeticholic acid), sales of which narrowly missed analyst expectations. Net losses at the New York-based company totaled $88.8 million vs. about $51 million in the third quarter of 2015, a period before Intercept made the jump to being a commercial company.